ArticleOncology letters2018
Clinical outcomes and associated factors of radioiodine-131 treatment in differentiated thyroid cancer with cervical lymph node metastasis.
Article in Oncology letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 13 citations in OpenAlex.
- Prognostic Factor Analysis for Risk-Stratified Papillary Thyroid Carcinoma and Nomogram Development for Predicting Structural Incomplete Response to Radioactive Iodine Therapy in Intermediate-Risk Patients.Cancer reports (Hoboken, N.J.) · 2026Article
- Limited effectiveness of radioiodine therapy for residual cervical lymph node metastases in radioiodine-naïve papillary thyroid cancer.Frontiers in endocrinology · 2026Article
- Role of Radioiodine in Cancer Therapy: A Review of the Design and Challenges in Selecting Radioligands from Natural Sources.Drug design, development and therapy · 2025Review
- Predictors of response to Radioactive Iodine Therapy in Intermediate and high risk patients with papillary thyroid carcinoma.BMC endocrine disorders · 2024Article
- Article
- Radioiodine (131I) treatment decision-making for low- and intermediate-risk differentiated thyroid cancer.Archives of endocrinology and metabolism · 2023Article
- The Role of Pre-ablative Stimulated Thyroglobulin and Thyroglobulin/Thyroid-Stimulating Hormone Ratio for Predicting Metastasis in Thyroid CancerMolecular imaging and radionuclide therapy · 2019Article
- Clinical predictors of I-131 therapy failure in differentiated thyroid cancer by machine learning: A single-center experience.World journal of nuclear medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical lymph node metastasis (CLNM) is common in differentiated thyroid cancer (DTC). Radioiodine-131 (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.